JPWO2020175253A1 - - Google Patents

Info

Publication number
JPWO2020175253A1
JPWO2020175253A1 JP2021502056A JP2021502056A JPWO2020175253A1 JP WO2020175253 A1 JPWO2020175253 A1 JP WO2020175253A1 JP 2021502056 A JP2021502056 A JP 2021502056A JP 2021502056 A JP2021502056 A JP 2021502056A JP WO2020175253 A1 JPWO2020175253 A1 JP WO2020175253A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021502056A
Other languages
Japanese (ja)
Other versions
JP7307427B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020175253A1 publication Critical patent/JPWO2020175253A1/ja
Application granted granted Critical
Publication of JP7307427B2 publication Critical patent/JP7307427B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021502056A 2019-02-26 2020-02-18 radiosensitizer Active JP7307427B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019046480 2019-02-26
JP2019046480 2019-02-26
PCT/JP2020/006381 WO2020175253A1 (en) 2019-02-26 2020-02-18 Radiosensitizer

Publications (2)

Publication Number Publication Date
JPWO2020175253A1 true JPWO2020175253A1 (en) 2020-09-03
JP7307427B2 JP7307427B2 (en) 2023-07-12

Family

ID=72239529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502056A Active JP7307427B2 (en) 2019-02-26 2020-02-18 radiosensitizer

Country Status (2)

Country Link
JP (1) JP7307427B2 (en)
WO (1) WO2020175253A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155239A (en) * 2007-12-26 2009-07-16 National Institute Of Advanced Industrial & Technology X-ray radiotherapy sensitizer
WO2015129535A1 (en) * 2014-02-25 2015-09-03 学校法人産業医科大学 Composition for inducing tumor immunity
WO2018193958A1 (en) * 2017-04-18 2018-10-25 Ｓｂｉファーマ株式会社 Enhancer of photodynamic effect in ala-pdt or ala-pdd

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155239A (en) * 2007-12-26 2009-07-16 National Institute Of Advanced Industrial & Technology X-ray radiotherapy sensitizer
WO2015129535A1 (en) * 2014-02-25 2015-09-03 学校法人産業医科大学 Composition for inducing tumor immunity
WO2018193958A1 (en) * 2017-04-18 2018-10-25 Ｓｂｉファーマ株式会社 Enhancer of photodynamic effect in ala-pdt or ala-pdd

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JIANG, HENG ET AL.: "Targeting antioxidant enzymes as a radiosensitizing strategy", CANCER LETTERS, vol. 438, JPN6020012113, 2018, pages 154 - 164, XP055735543, ISSN: 0004910845, DOI: 10.1016/j.canlet.2018.09.004 *
KALGHATGI, SAMEER ET AL.: "Bactericidal Antibiotics Induce Mitochondrial Dysfunction and Oxidative Damage in Mammalian Cells", SCI. TRANSL. MED., vol. Vol.5(192): 192ra85., JPN6020012111, 2013, ISSN: 0004910844 *
LABAY, EDWARDINE ET AL.: "Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers", ONCOTARGET, vol. Vol.7(23), JPN6020012109, 2016, pages 33919 - 33933, XP055735545, ISSN: 0004910843, DOI: 10.18632/oncotarget.8984 *
RASHEDUZZAMAN, MOHAMMAD ET AL.: "Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung canc", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, vol. 102, JPN6020012117, 2018, pages 20 - 30, XP085438685, ISSN: 0004910848, DOI: 10.1016/j.biocel.2018.06.006 *
TESSON, MATHIAS ET AL.: "Cell cycle specific radiosensitisation by the disulfiram and copper complex", ONCOTARGET, vol. Vol.8(39), JPN6020012116, 2017, pages 65900 - 65916, XP055735541, ISSN: 0004910847, DOI: 10.18632/oncotarget.19539 *
WANG, HUI ET AL.: "Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overprod", ONCOTARGET, vol. Vol.8(22), JPN6020012115, 2017, pages 35728 - 35742, XP055480285, ISSN: 0004910846, DOI: 10.18632/oncotarget.16113 *

Also Published As

Publication number Publication date
WO2020175253A1 (en) 2020-09-03
JP7307427B2 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
BR112019017762A2 (en)
BR112021017339A2 (en)
BR112021013854A2 (en)
BR112021018450A2 (en)
BR112021017939A2 (en)
BR112021017892A2 (en)
BR112019016141A2 (en)
BR112021017738A2 (en)
BR112021017782A2 (en)
BR112019016138A2 (en)
BR112019016142A2 (en)
BR112021018168A2 (en)
BR112021017728A2 (en)
AU2020104490A5 (en)
BR112021008711A2 (en)
BR112021018452A2 (en)
BR112021017234A2 (en)
BR112021017355A2 (en)
BR112021017703A2 (en)
BR112021018102A2 (en)
BR112021017173A2 (en)
BR112021018584A2 (en)
BR112021017637A2 (en)
BR112021015080A2 (en)
BR112021012348A2 (en)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230621

R150 Certificate of patent or registration of utility model

Ref document number: 7307427

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150